Tags

Type your tag names separated by a space and hit enter

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Expert Opin Pharmacother. 2012 Jun; 13(8):1177-86.EO

Abstract

INTRODUCTION

Bacterial resistance is increasing on a global basis, making treatment options more limited. The development of new agents to meet this threat is a matter of urgency. Ceftaroline fosamil , a member of an advanced cephalosporin class of antimicrobials, is currently approved by the US Food and Drug Administration for use in for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia. Ceftaroline displays activity against Gram-positive and Gram-negative bacteria, including both methicillin-susceptible and resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae (including penicillin- and ceftriaxone-resistant strains), respiratory pathogens (such as Moraxella catarrhalis and Haemophilus influenzae, including beta-lactamase-producing strains) and limited coverage against Enterobacteriaceae.

AREAS COVERED

Chemistry, mechanism of action, spectrum of activity, resistance, pharmacokinetics/pharmacodynamics, indications for use, safety and special populations are covered in this review.

EXPERT OPINION

Ceftaroline's unique activity against MRSA and penicillin- and ceftriaxone-resistant S. pneumoniae strains is due to its high affinity for penicillin binding protein (PBP)-2a and PBP-2x, respectively. In randomized, double-blinded, clinical trials, ceftaroline fosamil was found to be non-inferior to ceftriaxone for the treatment CABP and to vancomycin plus aztreonam for ABSSSI. Substantial differences between the cephalosporins exist. Ceftaroline has unique characteristics that may make it useful in specific clinical circumstances, especially against multi-drug-resistant Gram-positive organisms.

Links

Publisher Full Text

Authors+Show Affiliations

Casapao AM
Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Anti-Infective Research Laboratory, Pharmacy Practice, Detroit, MI 48201, USA.
Steed ME
No affiliation info available
Levine DP
No affiliation info available
Rybak MJ
No affiliation info available

MeSH

Anti-Bacterial AgentsCephalosporinsCommunity-Acquired InfectionsDrug Resistance, BacterialHumansPneumonia, BacterialSkin Diseases, Bacterial

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22594846

Citation

Casapao, Anthony M., et al. "Ceftaroline Fosamil for Community-acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection." Expert Opinion On Pharmacotherapy, vol. 13, no. 8, 2012, pp. 1177-86.
Casapao AM, Steed ME, Levine DP, et al. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opin Pharmacother. 2012;13(8):1177-86.
Casapao, A. M., Steed, M. E., Levine, D. P., & Rybak, M. J. (2012). Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Expert Opinion On Pharmacotherapy, 13(8), 1177-86. https://doi.org/10.1517/14656566.2012.685718
Casapao AM, et al. Ceftaroline Fosamil for Community-acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection. Expert Opin Pharmacother. 2012;13(8):1177-86. PubMed PMID: 22594846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. AU - Casapao,Anthony M, AU - Steed,Molly E, AU - Levine,Donald P, AU - Rybak,Michael J, PY - 2012/5/19/entrez PY - 2012/5/19/pubmed PY - 2012/9/12/medline SP - 1177 EP - 86 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 13 IS - 8 N2 - INTRODUCTION: Bacterial resistance is increasing on a global basis, making treatment options more limited. The development of new agents to meet this threat is a matter of urgency. Ceftaroline fosamil , a member of an advanced cephalosporin class of antimicrobials, is currently approved by the US Food and Drug Administration for use in for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia. Ceftaroline displays activity against Gram-positive and Gram-negative bacteria, including both methicillin-susceptible and resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae (including penicillin- and ceftriaxone-resistant strains), respiratory pathogens (such as Moraxella catarrhalis and Haemophilus influenzae, including beta-lactamase-producing strains) and limited coverage against Enterobacteriaceae. AREAS COVERED: Chemistry, mechanism of action, spectrum of activity, resistance, pharmacokinetics/pharmacodynamics, indications for use, safety and special populations are covered in this review. EXPERT OPINION: Ceftaroline's unique activity against MRSA and penicillin- and ceftriaxone-resistant S. pneumoniae strains is due to its high affinity for penicillin binding protein (PBP)-2a and PBP-2x, respectively. In randomized, double-blinded, clinical trials, ceftaroline fosamil was found to be non-inferior to ceftriaxone for the treatment CABP and to vancomycin plus aztreonam for ABSSSI. Substantial differences between the cephalosporins exist. Ceftaroline has unique characteristics that may make it useful in specific clinical circumstances, especially against multi-drug-resistant Gram-positive organisms. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/22594846/Ceftaroline_fosamil_for_community_acquired_bacterial_pneumonia_and_acute_bacterial_skin_and_skin_structure_infection_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.2012.685718 DB - PRIME DP - Unbound Medicine ER -